Taking peoplePhase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033
Key facts
- Who runs it
- First Tracks Biotherapeutics Inc.
- Where
- Belgium, Finland, Germany, Italy, Netherlands, Norway, and Spain19 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 48 people, planned
- Started
- 14 Nov 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 2 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Record updated
- 2 October 2026